Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Iamarangerboy who wrote (9819)	11/3/2006 1:40:37 AM
From: Vector1	Read Replies (2) of 10280

From Merrill Disaster scenario for Indiplon; slow cash bleed likely Neurocrine’s discussions with FDA have led to what we consider to be a disaster scenario for Indiplon – resubmission of the low dose “capsule” NDA will be delayed until Summer ‘08 and the high dose “tablet” submission will be delayed until ’09 – ’10 due to additional long-term safety and efficacy studies. We believe the opportunity for Indiplon – which will enter the market late and 2 years after generic Ambien launch at best – could be too small to justify further investment in the drug’s development. But, Neurocrine intends to continue spending on Indiplon & its pipeline, so we expect the stock to drift lower as it burns through its remaining cash. Maintain SELL.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next